• CSR Summary
• NCT00249132
• Primary Citation
• Data Specification

Approved Data Requests Associated with this Trial

• 2024-0280 : Individual-level and study-level predictors of placebo response and dropout in Schizophrenia Disorder clinical trials
• 2024-0008 : Sex differences in antipsychotic efficacy and side-effects in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
• 2022-5062 : Heterogeneous treatment effects estimation with multi-source data: evidence from bipolar disorder and schizophrenia trials
• 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
• 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
• 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
• 2021-4575 : A NOVEL METHOD TO SUMMARIZE SAFETY IN CLINICAL TRIALS USING PHARMACOLOGICAL CLASS-RELATED RISKS IN FAERS
• 2021-4568 : Motor side effects and antipsychotic efficacy of antipsychotic drugs: An individual participant meta-analysis
• 2020-4521 : Causally interpretable meta-analysis with missing data: Generalizing evidence from bipolar disorder and schizophrenia trials to a target population
• 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
• 2019-3941 : Factors moderating estimates of antipsychotic efficacy in schizophrenia
• 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
• 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
• 2017-1676 : Placebo Effects in Schizophrenia
• 2016-1005 : Identification of multivariate, clinical patterns predicting treatment response to paliperidone in schizophrenia
• 2016-0880 : Incidence of death and other SAEs related to second generation antipsychotic or placebo treatment in RCTs - a systematic review and meta-analysis
• 2016-0766 : Gastrointestinal disease impact on antipsychotic induced weight gain and metabolic syndrome in schizophrenia: analysis of randomized controlled trials
• 2015-0644 : Generalizing treatment effects for bipolar disorder and schizophrenia to the US population: Generalizability of network meta-analysis
• 2015-0592 : Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques
• 2014-0364 : Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual patient level analyses of placebo-controlled trials